O&M scoops £7m GlaxoSmithKline business

LONDON - Ogilvy & Mather has won at least an additional £7m of GlaxoSmithKline business in the UK from rival roster agencies Grey Worldwide and McCann-Erickson.

O&M has taken the Macleans toothpaste account in the UK from Grey, worth over £4 million. The agency has also taken the work for Zantac and Zovirax cold sore cream from McCann-Erickson in all countries in which it is sold over the counter. The account is worth £2 million in the UK.



Following the merger of SmithKline Beecham and Glaxo Wellcome at the end of last year and the subsequent acquisition of Block Drug, GlaxoSmithKline (GSK) has today announced a realignment its Consumer Healthcare creative advertising accounts. These changes are due to come into effect from January 2002.



A press statement said: "The main changes to existing account assignments will be as follows: Grey Worldwide will be responsible for all former Block Drug Sensodyne and Denture Care accounts with the exception of the UK and Japan where the incumbent agencies, PTK and Asatsu DK respectively, will be retained."



"Ogilvy & Mather will be appointed to handle the Zovirax, Zantac, Beconase and Eumovate brands in all countries where these products are marketed in over-the-counter form. O&M will also gain two oral care assignments: Macleans in the UK and Iodosan in Italy."



Over-the-counter medicine accounts in the US will be consolidated across four agencies: Grey, Publicis, Creative Advertising Services, and Arnold McGrath. The Phazyme brand will transfer from Grey to Publicis, Balmex will move from Grey to Creative Advertising Services, and Citrucel will move from O&M to Arnold McGrath.



The review does not affect agencies used by GSK's Pharmaceuticals business.



O&M declined to comment on the news.



If you have an opinion on this or any other issue raised on Brand Republic, join the debate in the Forum here.



Topics